Top

Published in:

01-11-2014 | Original Article

Cancer-related fatigue in patients before and after radical prostatectomy. Results of a prospective multi-centre study

Authors: Norbert Köhler, Lutz Gansera, Sigrun Holze, Michael Friedrich, Udo Rebmann, Jens-Uwe Stolzenburg, Michael C. Truss, Dirk Fahlenkamp, Hans-Jörg Scholz, Elmar Brähler

Published in: Supportive Care in Cancer | Issue 11/2014

Abstract

Purpose

A multi-centre, longitudinal study was conducted to assess the prevalence of fatigue amongst men with localized prostate cancer, to describe several dimensions of fatigue and to explore the predictability of fatigue by psychological distress and physical function.

Methods

The prevalence of fatigue was evaluated using the Multidimensional Fatigue Inventory in 329 prostate cancer patients before, 3, 6 and 12 months after surgery. Psychological distress was assessed using the Hospital Anxiety and Depression Scale. Physical function was measured using the EORTC QLQ-C30.

Results

After surgery, about 14 % of the patients were screened with chronic fatigue. For all dimensions of fatigue, only small longitudinal changes could be observed. Psychological distress could be identified as a good predictor of fatigue after but not before surgery.

Conclusions

Radical prostatectomy has no or little impact on the prevalence of fatigue. However, about 14 % of patients with chronic fatigue could possibly benefit from psychosomatic interventions. Interventions should consider the simultaneous appearance of fatigue and psychological distress and a reduced physical function.

Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71PubMedCrossRef

Wilt TJ, Brawer MK, Barry MJ et al (2009) The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 30(1):81–87PubMedCrossRef

Kyrdalen AE, Dahl AA, Hernes E et al (2010) Fatigue in hormone-naive prostate cancer patients treated with radical prostatectomy or definitive radiotherapy. Prostate Cancer Prostatic Dis 13(2):144–150PubMedCrossRef

Mock V, Atkinson A, Barsevick A (2000) NCCN practice guidelines for cancer-related fatigue. Oncology 14:151–161PubMed

Stone PC, Minton O (2008) Cancer-related fatigue. Eur J Cancer 44(8):1097–1104PubMedCrossRef

Piper BE, Cella D (2010) Cancer-related fatigue: definitions and clinical subtypes. JNCCN 8(8):958–966PubMed

Smets EMA, Garssen B, Bonke B et al (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39(3):315–325PubMedCrossRef

Hervouet S, Savard J, Simard SB et al (2005) Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery. J Pain Symptom Manag 30(5):474–484CrossRef

Storey DJ, McLaren DB, Atkinson MA et al (2012) Clinically relevant fatigue in recurrence-free prostate cancer survivors. Ann Oncol 23(1):65–72PubMedCrossRef

10.

Lilleby W, Fossa SD, Waehre HR et al (1998) Long-term morbidity and quality of life (QoL) in patients with localised prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 43(4):735–743CrossRef

11.

Maliski SL, Kwan L, Orecklin JR et al (2005) Predictors of fatigue after treatment for prostate cancer. Urology 65(1):101–108PubMedCrossRef

12.

Langston B, Armes J, Levy A et al (2013) The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer 21(6):1761–1771PubMedCrossRef

13.

Gelinas C, Fillion L (2004) Factors related to persistent fatigue following completion of breast cancer treatment. Oncol Nurs Forum 31(2):269–278PubMedCrossRef

14.

Servaes P, van der Werf S, Prins J et al (2001) Fatigue in disease-free cancer patients compared with fatigue in patients with chronic fatigue syndrome. Support Care Cancer 9(1):11–17PubMedCrossRef

15.

Haghighat S, Akbari ME, Holakouei K et al (2003) Factors predicting fatigue in breast cancer patients. Support Care Cancer 11(8):533–538PubMedCrossRef

16.

Kuhnt S, Ernst J, Singer S et al (2009) Fatigue in cancer survivors—prevalence and correlates. Onkologie 32(6):312–317PubMedCrossRef

17.

Reuter K, Harter M (2004) The concepts of fatigue and depression in cancer. Eur J Cancer Care 13(2):127–134CrossRef

18.

Schwarz R, Krauss O, Hinz A (2003) Fatigue in the general population. Onkologie 26(2):140–144PubMedCrossRef

19.

Smets EMA, Garssen B, Cull A et al (1996) Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. Brit J Cancer 73(2):241–245PubMedPubMedCentralCrossRef

20.

Seyidova-Khoshknabi D, Davis MP, Walsh D (2011) Review article: a systematic review of cancer-related fatigue measurement questionnaires. Am J Hosp Palliat Care 28(2):119–129PubMedCrossRef

21.

Minton O, Stone P (2009) A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 20(1):17–25PubMedCrossRef

22.

Fukuda K, Straus SE, Hickie I et al (1994) The chronic fatigue syndrome—a comprehensive approach to its definition and study. Ann Intern Med 121(12):953–959PubMedCrossRef

23.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370PubMedCrossRef

24.

Bjelland I, Dahl AA, Haug TT et al (2002) The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res 52(2):69–77PubMedCrossRef

25.

van Andel G, Bottomley A, Fosså SD et al (2008) An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 44(16):2418–2424PubMedCrossRef

26.

Herrmann C, Buss U, Snaith R (2011) HADS-D. Hospital anxiety and depression scale—Deutsche version. Hans Huber, Bern

27.

Hinz A, Krauss O, Stolzenburg JU et al (2009) Anxiety and depression in patients with prostate cancer and other urogenital cancer: a longitudinal study. Urol Oncol 27(4):367–372PubMedCrossRef

28.

Whelan-Goodinson R, Ponsford J, Schonberger M (2009) Validity of the hospital anxiety and depression scale to assess depression and anxiety following traumatic brain injury as compared with the structured clinical interview for DSM-IV. J Affect Disord 114(1–3):94–102PubMedCrossRef

29.

Aaronson NK (1993) The EORTC QLQ-C30—a quality-of-life instrument for use in international clinical trials in oncology. Qual Life Res 2(1):51–52

30.

Schumacher J, Klaiberg A, Brähler E (2003) Diagnostische Verfahren zu Lebensqualität und Wohlbefinden. Hogrefe, Göttingen, Bern, Toronto

31.

R Development Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna

32.

Wei T (2013) corrplot: visualization of a correlation matrix, Version 0.71. http://cran.r-project.org/web/packages/corrplot/corrplot.pdf. Accessed 29 July 2013

33.

Goedendorp MM, Gielissen MFM, Verhagen CAH et al (2008) Severe fatigue and related factors in cancer patients before the initiation of treatment. Brit J Cancer 99(9):1408–1414PubMedPubMedCentralCrossRef

34.

Koehler N, Gansera L, Stolzenburg JU et al (2012) Early continence in patients with localized prostate cancer. A comparison between open retropubic (RRPE) and endoscopic extraperitoneal radical prostatectomy (EERPE). Urol Oncol 30(6):798–803PubMedCrossRef

35.

Young KE, White CA (2006) The prevalence and moderators of fatigue in people who have been successfully treated for cancer. J Psychosom Res 60(1):29–38PubMedCrossRef

Title: Cancer-related fatigue in patients before and after radical prostatectomy. Results of a prospective multi-centre study
Authors: Norbert Köhler
Lutz Gansera
Sigrun Holze
Michael Friedrich
Udo Rebmann
Jens-Uwe Stolzenburg
Michael C. Truss
Dirk Fahlenkamp
Hans-Jörg Scholz
Elmar Brähler
Publication date: 01-11-2014
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 11/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2265-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2014

Coping with oral cancer: the impact of health and disease-related personality traits

Effects of professional oral health care on reducing the risk of chemotherapy-induced oral mucositis

I want to fly home: a terminal cancer patient’s right to go home

Worrying about one’s children after breast cancer diagnosis: desired timing of psychosocial intervention

Neurobehavioural changes in patients following brain tumour: patients and relatives perspective

Quantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events: the somatic burden score

Keynote webinar | Spotlight on antibody–drug conjugates in cancer